MLLT6

MLLT6 (AF17) is a nuclear zinc finger/leucine-zipper protein that acts as a chromatin-associated transcriptional regulator (PMID:8058765). Its best-characterized mechanism is competition with AF9 for binding to the same domain of the H3 K79 methyltransferase Dot1a: MLLT6 redirects Dot1a from the nucleus to the cytoplasm in a leptomycin B-sensitive manner, lowers H3 K79 methylation, and relieves Dot1a·AF9-mediated gene repression (PMID:19864429). In renal collecting duct cells this axis derepresses the ENaC subunits (α, β, γ) and Sgk1 to enhance Na+ transport, and Af17-deficient mice display elevated H3 K79 dimethylation, reduced ENaC activity, increased sodium excretion, and lower blood pressure, with these effects compensated by high aldosterone (PMID:22087315, PMID:21546577). MLLT6 also functions in transcriptional activation through chromatin remodeling: it complexes with ATF2 to establish active chromatin at the DDIT3/4 promoters and drive breast cancer cell apoptosis (PMID:38757913), and it supports STAT1 signaling required for IFN-γ-induced PD-L1 expression and antigen-presentation gene induction, modulating CD8+ T cell-mediated cytolysis (PMID:33063451). The N-terminal cysteine-rich domain is retained alongside the leucine-zipper dimerization motif 3' of the MLL breakpoint in t(11;17) acute leukemia fusions, and the dimerization domain is implicated in leukemogenic activity of MLL-AF17 (PMID:8058765, PMID:16105757). Beyond these contexts, MLLT6 is a β-catenin/TCF transcriptional target that promotes cell growth and G2-M progression (PMID:11522623).

1. 1994 Medium

   Establishing the molecular identity of the t(11;17) MLL fusion partner defined MLLT6 as a leucine-zipper/zinc-finger protein and located the dimerization motif 3' of the breakpoint, framing a structural basis for its leukemogenic contribution.

   Evidence cDNA cloning and sequence/domain analysis of AF17 fused to MLL in t(11;17) AML

   PMID:8058765

   Open questions at the time

   • No functional mutagenesis of the leucine zipper in this work
   • DNA-binding or partner activity of the zinc-finger domain not tested
2. 1995 Low

   Classifying the N-terminal cysteine-rich domain as a LAP zinc-finger motif shared with AF10 proposed a DNA-binding function for MLLT6.

   Evidence Sequence homology analysis of the LAP finger consensus across 25 proteins including MLLT6

   PMID:7568208

   Open questions at the time

   • Computational prediction only — no biochemical validation of zinc or DNA binding for MLLT6
   • No demonstration of a specific DNA target
3. 2001 Medium

   Placing MLLT6 downstream of Wnt signaling connected it to proliferative control, showing it is a β-catenin/TCF target that drives G2-M progression.

   Evidence cDNA microarray, β-catenin accumulation assays, overexpression and FACS cell-cycle analysis in NIH3T3 cells

   PMID:11522623

   Open questions at the time

   • Mechanism linking MLLT6 to G2-M transition not defined
   • No direct transcriptional targets identified in this context
4. 2001 Medium

   Ortholog genetics established an in vivo requirement for the AF17/AF10 family in maintaining cell-type-specific gene expression.

   Evidence P-element mutagenesis, immunostaining, and neuron-specific transgenic rescue of the Drosophila ortholog Dalf

   PMID:11165485

   Open questions at the time

   • Molecular partners of Dalf not identified
   • Relevance to mammalian MLLT6 mechanism inferred from orthology only
5. 2009 High

   Defining MLLT6 as a competitive Dot1a-binding partner of AF9 revealed its core mechanism: controlling Dot1a nucleocytoplasmic localization to set H3 K79 methylation and relieve gene repression.

   Evidence Competitive Co-IP/pulldown, luciferase reporters, RNAi, leptomycin B localization, and patch clamp in HEK 293T cells

   PMID:19864429

   Open questions at the time

   • Nuclear export signal/mechanism driving Dot1a relocalization not mapped
   • Scope of repressed targets beyond α-ENaC not delineated
6. 2011 High

   Tissue-level and in vivo work tied the MLLT6–Dot1a axis to ENaC-dependent sodium handling and blood pressure, with aldosterone acting as a compensating input.

   Evidence Reciprocal OE/knockdown with ChIP and electrophysiology in M-1 cells, plus Af17-knockout mice with blood pressure, sodium, and channel assays

   PMID:21546577 PMID:22087315

   Open questions at the time

   • Crosstalk between MLLT6 and aldosterone signaling at the molecular level unresolved
   • Whether the same axis operates in non-renal tissues not addressed
7. 2020 High

   A CRISPR screen extended MLLT6 function into immune evasion, showing it supports STAT1 signaling and IFN-γ-induced PD-L1 and antigen-presentation gene expression in cancer cells.

   Evidence Genome-wide CRISPR screen, MLLT6 knockout, PD-L1 flow cytometry, STAT1 readouts, IFN-γ stimulation, and T cell cytolysis co-culture in human cancer cells

   PMID:33063451

   Open questions at the time

   • Direct molecular link between MLLT6 and STAT1 not defined
   • Whether the Dot1a/H3 K79 mechanism underlies this immune phenotype unknown
8. 2024 Medium

   Identifying the MLLT6/ATF2 complex showed MLLT6 can act as a transcriptional activator establishing active chromatin to drive a pro-apoptotic DDIT3/4 program.

   Evidence Co-IP, chromatin assays at DDIT3/4 promoters, RNA profiling, stable knockdown with restoration, and in vivo colonization assays in breast cancer

   PMID:38757913

   Open questions at the time

   • Direct vs indirect nature of MLLT6 recruitment to DDIT3/4 promoters not resolved
   • Reciprocal validation of the ATF2 interaction limited to single-lab Co-IP

• How MLLT6's distinct activities — Dot1a relocalization/repression relief, ATF2-driven activation, and STAT1 support — are integrated through its zinc-finger and leucine-zipper domains remains unresolved.
• No structural model of MLLT6 domain function in any complex
• Direct DNA-binding activity of the LAP zinc finger never demonstrated
• Unifying mechanism across renal, oncogenic, and immune contexts unknown